Treating ALK-positive non-small cell lung cancer
نویسندگان
چکیده
منابع مشابه
Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
Authors' disclosures of potential conflicts of interest are found at the end of this article. A ccording to the American Cancer Society (ACS), lung cancer is the second most common diagnosis in the world and is the leading cause of death from malignancy in both men and women (ACS, 2014). Lung cancer accounts for 13% of new diagnoses and 27% of deaths from malig-nancy. The ACS (2014) estimated t...
متن کاملFuture of ALK inhibition in non-small-cell lung cancer.
Progress in defi ning molecular targets of oncogenesis and drugs to inhibit cancer growth in specifi c populations has led to augmented outcomes for patients and new expectations in the development of treatments. The EML4–ALK fusion protein was identifi ed in patients with non-small-cell lung cancer (NSCLC) in 2007. Rearrangements in the ALK gene lead to constitutive signalling, triggering tran...
متن کاملALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ALK has been associated with other types of cancers, including non-small-cell ...
متن کاملALK inhibitors and advanced non-small cell lung cancer (review).
Treatment of unselected patients with advanced non-small cell lung cancer (NSCLC) receiving third-generation platinum-based chemotherapy has reached a plateau of effectiveness. Histology and molecular analyses are the cornerstone in the initial diagnosis of NSCLC and are key determinants to address the appropriate strategy of treatment. In non-squamous histology the combination of cisplatin plu...
متن کاملFirst-line treatment of advanced ALK-positive non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer deaths, both within the US and worldwide. There have been major treatment advances in NSCLC over the past decade with the discovery of molecular drivers of NSCLC, which has ushered in an era of personalized medicine. There are several actionable genetic aberrations in NSCLC, such as epidermal growth factor receptor and an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Translational Medicine
سال: 2018
ISSN: 2305-5839,2305-5847
DOI: 10.21037/atm.2017.11.34